Steve Gourlay joins Power CEO, Brandon Li, to discuss Actinogen's innovative approach to Alzheimer's treatment. Steven shares his background in clinical trials and drug development, highlighting the potential of the company's lead molecule, Xanamem, a daily pill aimed at reducing brain cortisol levels. Their conversation covers the challenges in Alzheimer's & depression research and the promising early clinical data. Steven sheds insight on the strategic focus on Alzheimer's over depression due to unmet medical needs and the future direction in Alzheimer's research. Brandon and Steven also dive into the regulatory landscape, patient selection criteria, and the broader implications of Actinogen's work in transforming the treatment landscape for neurodegenerative diseases.

Ver todos los episodios